Macquarie Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Macquarie Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-178	Closed	-$21K	–	1866
2022 Q3	$21K	Sell	178 -220	-55%	-$12.9K	﹤0.01%	2179
2022 Q2	$19K	Hold	398	–	–	﹤0.01%	2324
2022 Q1	$28	Hold	398	–	–	﹤0.01%	2311
2021 Q4	$30K	Hold	398	–	–	﹤0.01%	2299
2021 Q3	$23K	Hold	398	–	–	﹤0.01%	2423
2021 Q2	$18K	Hold	398	–	–	﹤0.01%	2377
2021 Q1	$20K	Sell	398 -105	-21%	-$5.24K	﹤0.01%	2280
2020 Q4	$21K	Hold	503	–	–	﹤0.01%	2211
2020 Q3	$23K	Hold	503	–	–	﹤0.01%	2138
2020 Q2	$25K	Buy	+503	New	+$26K	﹤0.01%	2120
2018 Q1	–	Sell	-2,700	Closed	-$158K	–	2221
2017 Q4	$158K	Buy	2,700 +2,100	+350%	+$105K	﹤0.01%	1797
2017 Q3	$28K	Buy	+600	New	+$24.1K	﹤0.01%	2065

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Macquarie Group's ENTA Position: Q4 2022 in Review

Macquarie Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2022, closing a stake of 178 shares — an estimated $21K sold.

Macquarie Group first reported a position in ENTA in Q3 2017 and held it in 12 quarters. The position peaked at $158K in Q4 2017. 146 funds tracked by Wall St. Rank hold ENTA as of Q4 2022.

Macquarie Group reported no remaining Enanta Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 178 Enanta Pharmaceuticals shares in Q4 2022, an estimated $21K.
Macquarie Group first reported a position in Enanta Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Macquarie Group's Enanta Pharmaceuticals position peaked at $158K in Q4 2017.
146 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.